ProtiFi

ProtiFi

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.2M

Overview

ProtiFi is a private, commercial-stage company that has established itself as a leader in omics sample preparation technology since its founding in 2018. Its core business revolves around physical consumables (kits, plates, columns) and a complementary SaaS data analysis platform, catering primarily to academic, pharmaceutical, and research laboratories. The company's value proposition is built on demonstrable improvements in reproducibility, recovery rates, and workflow speed, as evidenced by widespread adoption and citations in thousands of scientific papers. ProtiFi operates in the rapidly growing proteomics and multi-omics tools market, with a clear focus on enabling precision biology through robust sample prep and data interpretation.

ProteomicsAI / Machine Learning

Technology Platform

Proteomics and multi-omics sample preparation technology (S-Trap, Si-Trap, Tryp-N) combined with a cloud-based data analysis and visualization platform (SimpliFi).

Funding History

2
Total raised:$6.2M
Series A$5M
Seed$1.2M

Opportunities

The global expansion of proteomics and multi-omics research in both academia and pharma drives demand for reliable, high-throughput sample prep tools.
The growing complexity of omics data creates a significant need for user-friendly bioinformatics platforms like SimpliFi, opening a software-as-a-service revenue stream.

Risk Factors

Intense competition from large, established life science tools companies and agile startups could pressure market share and pricing.
Technological disruption in sample preparation methods could render current products less critical.
The business is exposed to cyclical swings in research and development funding across its customer base.

Competitive Landscape

ProtiFi competes in the sample prep segment against large vendors like Thermo Fisher Scientific (Pierce kits), Bio-Rad, and MilliporeSigma, as well as specialized proteomics companies. For data analysis, it competes with a wide range of bioinformatics software from open-source projects (e.g., MaxQuant, Skyline) to commercial platforms (e.g., Biognosys' Spectronaut, Thermo's Proteome Discoverer). Its differentiation lies in the specific performance of S-Trap for challenging samples and the integrated, accessible nature of its SimpliFi platform.